Earnings Releases·Nov 12, 2026, 4:30 PM ET

Aethlon Medical — Second Quarter Fiscal 2027 Earnings Summary

Consolidated operating expenses rose 77.2% to $2.7 million and net loss widened to $2.62 million per share ($2.60) for the quarter ended September 30, 2026, driven primarily by higher professional fees related to the proposed merger and the absence of a research and development tax credit.
The company entered a definitive Plan of Merger with North Immunology, Inc. on September 17, 2026, to form a combined entity operating under the name North Immunology, Inc., with legacy Hemopurifier business holders receiving contingent value rights (CVRs) upon closing.
Cash and cash equivalents increased to $6.5 million as of September 30, 2026, from $5.0 million in March 2026, while total stockholders' equity grew to $6.05 million, though the accumulated deficit expanded to $(179.3) million.
Clinical progress included treating the second participant in the final dosing cohort of the Phase 1 oncology study in Australia, bringing the total patient count to eight, with management targeting the conclusion of recruitment to compile data for analysis.
Workforce reductions were implemented near the quarter's end, and the company faces risks regarding the completion of the merger, potential failure to satisfy Nasdaq listing requirements, and the uncertainty of legacy business monetization.